Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Pulmonary Arterial Hypertension (PAH) Drugs market report explains the definition, types, applications, major countries, and major players of the Pulmonary Arterial Hypertension (PAH) Drugs market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
United Therapeutics
Berlin Cures
Actelion Pharmaceuticals
Merck
Northern Therapeutics
Novartis
AstraZeneca
Daiichi Sankyo
Reata Pharmaceuticals
Aires Pharmaceuticals
Eiger BioPharmaceuticals
Glaxosmithkline
Pfizer
Arena Pharmaceuticals
Bayer Healthcare
By Type:
Inhalation
Injectables
Oral Administration
By End-User:
Hospitals
Clinics
Other
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Pulmonary Arterial Hypertension (PAH) Drugs Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Pulmonary Arterial Hypertension (PAH) Drugs Outlook to 2028- Original Forecasts
-
2.2 Pulmonary Arterial Hypertension (PAH) Drugs Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Pulmonary Arterial Hypertension (PAH) Drugs Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Pulmonary Arterial Hypertension (PAH) Drugs Market- Recent Developments
-
6.1 Pulmonary Arterial Hypertension (PAH) Drugs Market News and Developments
-
6.2 Pulmonary Arterial Hypertension (PAH) Drugs Market Deals Landscape
7 Pulmonary Arterial Hypertension (PAH) Drugs Raw Materials and Cost Structure Analysis
-
7.1 Pulmonary Arterial Hypertension (PAH) Drugs Key Raw Materials
-
7.2 Pulmonary Arterial Hypertension (PAH) Drugs Price Trend of Key Raw Materials
-
7.3 Pulmonary Arterial Hypertension (PAH) Drugs Key Suppliers of Raw Materials
-
7.4 Pulmonary Arterial Hypertension (PAH) Drugs Market Concentration Rate of Raw Materials
-
7.5 Pulmonary Arterial Hypertension (PAH) Drugs Cost Structure Analysis
-
7.5.1 Pulmonary Arterial Hypertension (PAH) Drugs Raw Materials Analysis
-
7.5.2 Pulmonary Arterial Hypertension (PAH) Drugs Labor Cost Analysis
-
7.5.3 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Expenses Analysis
8 Global Pulmonary Arterial Hypertension (PAH) Drugs Import and Export Analysis (Top 10 Countries)
-
8.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Export by Region (Top 10 Countries) (2017-2028)
9 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Inhalation Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Injectables Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Oral Administration Consumption and Growth Rate (2017-2022)
-
9.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Other Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis and Outlook till 2022
-
10.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.2.2 Canada Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.2.3 Mexico Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.3.2 UK Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.3.3 Spain Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.3.4 Belgium Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.3.5 France Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.3.6 Italy Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.3.7 Denmark Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.3.8 Finland Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.3.9 Norway Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.3.10 Sweden Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.3.11 Poland Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.3.12 Russia Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.3.13 Turkey Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.4.2 Japan Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.4.3 India Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.4.4 South Korea Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.4.5 Pakistan Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.4.6 Bangladesh Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.4.7 Indonesia Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.4.8 Thailand Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.4.9 Singapore Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.4.10 Malaysia Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.4.11 Philippines Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.4.12 Vietnam Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.5.2 Colombia Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.5.3 Chile Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.5.4 Argentina Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.5.5 Venezuela Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.5.6 Peru Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.5.7 Puerto Rico Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.5.8 Ecuador Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.6.2 Kuwait Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.6.3 Oman Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.6.4 Qatar Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.6.5 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.6.6 United Arab Emirates Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.7.2 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.7.3 Egypt Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.7.4 Algeria Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
-
10.8.2 New Zealand Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)
11 Global Pulmonary Arterial Hypertension (PAH) Drugs Competitive Analysis
-
11.1 United Therapeutics
-
11.1.1 United Therapeutics Company Details
-
11.1.2 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.1.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Berlin Cures
-
11.2.1 Berlin Cures Company Details
-
11.2.2 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.2.4 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Actelion Pharmaceuticals
-
11.3.1 Actelion Pharmaceuticals Company Details
-
11.3.2 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.3.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Merck
-
11.4.1 Merck Company Details
-
11.4.2 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.4.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Northern Therapeutics
-
11.5.1 Northern Therapeutics Company Details
-
11.5.2 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.5.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Novartis
-
11.6.1 Novartis Company Details
-
11.6.2 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.6.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 AstraZeneca
-
11.7.1 AstraZeneca Company Details
-
11.7.2 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.7.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Daiichi Sankyo
-
11.8.1 Daiichi Sankyo Company Details
-
11.8.2 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.8.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Reata Pharmaceuticals
-
11.9.1 Reata Pharmaceuticals Company Details
-
11.9.2 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.9.4 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Aires Pharmaceuticals
-
11.10.1 Aires Pharmaceuticals Company Details
-
11.10.2 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.10.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Eiger BioPharmaceuticals
-
11.11.1 Eiger BioPharmaceuticals Company Details
-
11.11.2 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.11.4 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Glaxosmithkline
-
11.12.1 Glaxosmithkline Company Details
-
11.12.2 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.12.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Pfizer
-
11.13.1 Pfizer Company Details
-
11.13.2 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.13.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Arena Pharmaceuticals
-
11.14.1 Arena Pharmaceuticals Company Details
-
11.14.2 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.14.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Bayer Healthcare
-
11.15.1 Bayer Healthcare Company Details
-
11.15.2 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
11.15.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
11.15.5 Recent Research and Development Strategies
12 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Outlook by Types and Applications to 2028
-
12.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Inhalation Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Injectables Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Oral Administration Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis and Outlook to 2028
-
13.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.2.2 Canada Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.2.3 Mexico Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.3.2 UK Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.3.3 Spain Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.3.4 Belgium Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.3.5 France Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.3.6 Italy Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.3.7 Denmark Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.3.8 Finland Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.3.9 Norway Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.3.10 Sweden Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.3.11 Poland Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.3.12 Russia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.3.13 Turkey Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.4.2 Japan Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.4.3 India Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.4.4 South Korea Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.4.8 Thailand Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.4.9 Singapore Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.4.11 Philippines Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.5.2 Colombia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.5.3 Chile Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.5.4 Argentina Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.5.6 Peru Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.6.3 Oman Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.6.4 Qatar Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.7.2 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.7.3 Egypt Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.7.4 Algeria Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Pulmonary Arterial Hypertension (PAH) Drugs
-
Figure of Pulmonary Arterial Hypertension (PAH) Drugs Picture
-
Table Global Pulmonary Arterial Hypertension (PAH) Drugs Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Pulmonary Arterial Hypertension (PAH) Drugs Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Inhalation Consumption and Growth Rate (2017-2022)
-
Figure Global Injectables Consumption and Growth Rate (2017-2022)
-
Figure Global Oral Administration Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Country (2017-2022)
-
Table North America Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Country (2017-2022)
-
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Canada Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Mexico Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Country (2017-2022)
-
Figure Germany Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure UK Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Spain Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Belgium Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure France Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Italy Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Denmark Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Finland Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Norway Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Sweden Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Poland Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Russia Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Turkey Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Table APAC Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Country (2017-2022)
-
Figure China Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Thailand Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Singapore Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Philippines Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Table South America Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Country (2017-2022)
-
Figure Brazil Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Colombia Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Chile Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Argentina Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Peru Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Table GCC Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Country (2017-2022)
-
Figure Bahrain Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Oman Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Qatar Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Country (2017-2022)
-
Figure Nigeria Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Africa Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Egypt Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Algeria Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Table Oceania Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Country (2017-2022)
-
Figure Australia Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)
-
Table United Therapeutics Company Details
-
Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Table Berlin Cures Company Details
-
Table Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Table Actelion Pharmaceuticals Company Details
-
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Table Merck Company Details
-
Table Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Table Northern Therapeutics Company Details
-
Table Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Table Novartis Company Details
-
Table Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Table AstraZeneca Company Details
-
Table AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Table Daiichi Sankyo Company Details
-
Table Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Table Reata Pharmaceuticals Company Details
-
Table Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Table Aires Pharmaceuticals Company Details
-
Table Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Table Eiger BioPharmaceuticals Company Details
-
Table Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Table Glaxosmithkline Company Details
-
Table Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Table Arena Pharmaceuticals Company Details
-
Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Table Bayer Healthcare Company Details
-
Table Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Main Business and Markets Served
-
Table Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
-
Figure Global Inhalation Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Injectables Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Oral Administration Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast by Country (2022-2028)
-
Table North America Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Germany Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast by Country (2022-2028)
-
Figure China Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Brazil Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Australia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
